GENinCode PLC - Grant of Share Options & PDMR Dealings
GENinCode Plc
("GENinCode" or the "Company")
Grant of Share Options, Surrender of Existing Options & PDMR Dealings
GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that the Company has approved the grant of options over an aggregate of 83,847,292 new ordinary shares of
Background to the New Options grants
The Company adopted the 2021 Share Option Plan to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. The New Options replace 29,856,434 current options ("Existing Options") held by existing option holders, which will be surrendered, and are new grants to those employees who have more recently joined the Group.
Terms of the New Options
The New Options have an exercise price of
Surrender of Existing Options
In
For directors and employees the existing options will be surrendered for no consideration (the "Option Surrender"), details for which are outlined below. The board believe it is appropriate to issue new share options in replacement of the existing ones to reflect the Company's current share price and to properly incentivise its employees, including its management.
Details of resultant holdings
Following the New Options grant and the Option Surrender, details of options held by Directors, PDMRs and other employees of the Company, are as follows:
|
Director's name |
Position |
Number of options surrendered |
Number of New Options granted at |
Aggregate number of options post grant |
Current total beneficial holding of Ordinary Shares |
Current holding as a % of Issued share capital |
|
|
CEO |
5,254,832 |
30,428,453 |
30,428,453 |
14,235,473 |
1.89% |
|
|
CFO |
4,790,062 |
13,523,757 |
13,523,757 |
2,773,587 |
0.37% |
|
|
COO |
3,161,274 |
21,976,105 |
21,976,105 |
15,237,636 |
2.02% |
|
|
Non-Executive Chair |
1,197,516 |
1,267,852 |
1,267,852 |
- |
0.00% |
|
|
Non-Executive Director |
837,423 |
1,267,852 |
1,267,852 |
1,905,405 |
0.25% |
|
|
Non-Executive Director |
837,423 |
845,235 |
845,235 |
600,000 |
0.08% |
|
|
Non-Executive Director |
172,188 |
2,535,704 |
2,535,704 |
24,917,243 |
3.31% |
|
Other Employees |
|
13,605,716 |
12,002,334 |
14,078,585 |
N/A |
N/A |
|
Total: |
|
29,856,434 |
83,847,292 |
85,923,543 |
58,395,757 |
7.75% |
Directors and employees of the Group surrendered Options over an aggregate of 29,856,434 Ordinary Shares. The grant of 71,844,958 New Options exercisable at
Following the grant of the New Options and the Options Surrender, there are Options over a total of 85,923,543 Ordinary Shares in the Company as at the date of this announcement, representing approximately 11.41% of the Company's existing issued share capital.
For more information visit www.genincode.com
Enquiries:
|
GENinCode Plc |
www.genincode.com or via Walbrook PR |
|
|
|
|
|
|
|
Cavendish Capital Markets Limited |
Tel: +44 (0) 20 7220 0500 |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or |
|
|
About GENinCode:
GENinCode Plc is a
GENinCode operates business units in the
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease.
The notification set out below is provided in accordance with the requirements of MAR.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|
|||||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
||||||||
|
a. |
Name |
1. 2. 3. 4. 5. 6. 7.
|
|
|||||||
|
2 |
Reason for notification |
|
||||||||
|
a. |
Position/Status |
1. Chief Executive Officer 2. Chief Financial Officer 3. Chief Operating Officer 4. Non-Executive Chair 5. Non-Executive Director 6. Non-Executive Director 7. Non-Executive Director |
|
|||||||
|
b. |
Initial notification/ Amendment |
Initial Notification |
|
|||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
||||||||
|
a. |
Name |
GENinCode Plc |
|
|||||||
|
b. |
LEI |
213800UX6TE7K65O2892 |
|
|||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
||||||||
|
a. |
Description of the financial instrument, type of instrument |
Options over Ordinary Shares of 1p each
N/A |
|
|||||||
|
b. |
Nature of the transaction |
Grant of options under the 2021 Share Option Plan with time vesting conditions attached |
|
|||||||
|
c. |
Price(s) and volume(s) |
|
|
Exercise Price(s) |
Volume(s) |
|
|
|||
|
|
1. |
|
30,428,453 |
|
|
|||||
|
2. |
|
13,523,757 |
|
|
||||||
|
|
3. |
|
21,976,105 |
|
|
|||||
|
|
4. |
|
1,267,852 |
|
|
|||||
|
|
5. |
|
1,267,852 |
|
|
|||||
|
|
6. |
|
845,235 |
|
|
|||||
|
|
7. |
1 pence |
2,535,704 |
|
|
|||||
|
|
|
|||||||||
|
d. |
Aggregated information - Aggregated Volume - Price |
See above |
|
|||||||
|
e. |
Date of the transaction |
|
|
|||||||
|
f. |
Place of the transaction |
Outside a trading venue |
|
|||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE